Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bamlanivimab At-Home Infusion for Mild-to-Moderate COVID-19
NCT04656691Phase 4Terminated
- Start
- Jan 2021
- Primary completion
- Apr 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of bamlanivimab in coronavirus disease 2019 (COVID-19). Primary endpoint: Number of Participants With Incidence of COVID-19 Related Hospitalization at Day 28. Started Jan 2021; status: terminated.
02
Drugs
bamlanivimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04656691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04656691.